Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2023	$ 18,625	$ 42	$ 129,763	$ (150,741)	$ (2,311)
Balance, shares at Dec. 31, 2023	18,625	42,329,864
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan			4		4
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares		3,333
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			744		744
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			189		189
Purchase - Employee Stock Purchase Plan		$ 1	352		353
Purchase - Employee Stock Purchase Plan, shares		511,884
Net loss				(10,612)	(10,612)
Vest - restricted stock awards
Vest - restricted stock awards, shares		26,912
Conversions - Senior Secured Convertible Note		$ 1	687		688
Conversions - Senior Secured Convertible Note, shares		543,298
Issuance - Series A-1 Preferred Stock	$ 5,670				5,670
Issuance - Series A-1 Preferred Stock, shares	5,670
Exchange - Series A and Series A-1 Preferred Stock	$ (24,295)			(7,496)	(31,791)
Exchange - Series A and Series A-1 Preferred Stock, shares	(24,295)
Issuance through exchange - Series B Preferred Stock	$ 31,790				31,790
Issuance through exchange - Series B Preferred Stock, shares	31,790
Issuance through sale- Series B Preferred Stock	$ 12,495				12,495
Issuance through sale- Series B Preferred Stock, shares	12,495
Issuance - Due To: PAVmed Inc. Settlement in Common Stock		$ 3	4,672		4,675
Issuance - Due To: PAVmed Inc. Settlement in Common Stock, shares		3,331,771
Balance at Mar. 31, 2024	$ 44,285	$ 47	136,411	(168,849)	11,894
Balance, shares at Mar. 31, 2024	44,285	46,747,062
Balance at Dec. 31, 2024	$ 54,419	$ 63	154,675	(203,766)	5,391
Balance, shares at Dec. 31, 2024	54,419	63,071,950
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan			3		$ 3
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares		1,893			1,893
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			949		$ 949
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			81		81
Purchase - Employee Stock Purchase Plan			141		141
Purchase - Employee Stock Purchase Plan, shares		203,051
Issuance - Interest payment paid in stock			32		32
Issuance - Interest payment paid in stock, shares		40,767
Issuance - Registered Direct Offering, net of fees		$ 14	14,920		14,934
Issuance - Registered Direct Offering, net of fees, shares		13,939,331
Issuance - Dividend on Series B Preferred Stock		$ 7	9,103	(9,110)
Issuance - Dividend on Series B Preferred Stock, shares		7,117,463
Net loss				(26,908)	(26,908)
Balance at Mar. 31, 2025	$ 54,419	$ 84	$ 179,904	$ (239,784)	$ (5,377)
Balance, shares at Mar. 31, 2025	54,419	84,374,455